TransMedics Group (NASDAQ:TMDX) Reaches New 1-Year Low – Here’s Why

TransMedics Group, Inc. (NASDAQ:TMDX) shares hit a new 52-week low during trading on Thursday . The company traded as low as $57.90 and last traded at $58.02, with a volume of 2203853 shares trading hands. The stock had previously closed at $60.44.

Wall Street Analysts Forecast Growth

TMDX has been the subject of a number of research analyst reports. Baird R W upgraded shares of TransMedics Group to a “strong-buy” rating in a research report on Tuesday, September 24th. Needham & Company LLC reiterated a “hold” rating on shares of TransMedics Group in a report on Wednesday, December 11th. Robert W. Baird lowered their target price on TransMedics Group from $150.00 to $120.00 and set an “outperform” rating on the stock in a research note on Wednesday, December 11th. JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $75.00 price target (down from $116.00) on shares of TransMedics Group in a research note on Tuesday, December 17th. Finally, TD Cowen decreased their target price on TransMedics Group from $175.00 to $120.00 and set a “buy” rating for the company in a research report on Monday, November 18th. Three analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $122.70.

TransMedics Group Price Performance

The company has a market cap of $1.95 billion, a price-to-earnings ratio of 61.72 and a beta of 2.12. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. The company has a fifty day moving average price of $72.63 and a two-hundred day moving average price of $119.17.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings data on Monday, October 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). The business had revenue of $108.76 million during the quarter, compared to analyst estimates of $115.00 million. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The company’s quarterly revenue was up 63.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.12) EPS. As a group, equities research analysts anticipate that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

Insider Buying and Selling

In other TransMedics Group news, insider Tamer I. Khayal sold 1,084 shares of TransMedics Group stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $86.40, for a total transaction of $93,657.60. Following the completion of the transaction, the insider now directly owns 20,843 shares of the company’s stock, valued at approximately $1,800,835.20. This trade represents a 4.94 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Edward M. Basile sold 6,750 shares of the stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $83.55, for a total transaction of $563,962.50. Following the sale, the director now owns 732 shares of the company’s stock, valued at $61,158.60. This trade represents a 90.22 % decrease in their position. The disclosure for this sale can be found here. 7.00% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. State of Alaska Department of Revenue bought a new position in TransMedics Group in the 3rd quarter valued at $2,560,000. Charles Schwab Investment Management Inc. raised its holdings in shares of TransMedics Group by 2.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 271,694 shares of the company’s stock valued at $42,656,000 after buying an additional 6,634 shares during the last quarter. Zacks Investment Management bought a new position in shares of TransMedics Group in the third quarter valued at about $1,607,000. Vaughan Nelson Investment Management L.P. lifted its position in TransMedics Group by 24.3% during the 3rd quarter. Vaughan Nelson Investment Management L.P. now owns 329,010 shares of the company’s stock worth $51,654,000 after buying an additional 64,360 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. grew its holdings in TransMedics Group by 665.1% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 74,625 shares of the company’s stock worth $11,716,000 after acquiring an additional 64,872 shares during the last quarter. Institutional investors own 99.67% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.